SHPH saw its Momentum Indicator move above the 0 level on September 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 62 similar instances where the indicator turned positive. In 54 of the 62 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
SHPH moved above its 50-day moving average on September 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SHPH crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +7.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where SHPH advanced for three days, in 133 of 161 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 33 of 45 cases where SHPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
The 10-day RSI Indicator for SHPH moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In 8 of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 28 cases where SHPH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SHPH turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 32 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SHPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SHPH broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.197) is normal, around the industry mean (11.138). P/E Ratio (0.498) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. SHPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SHPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
YCBD saw its Momentum Indicator move below the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 105 similar instances where the indicator turned negative. In 95 of the 105 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where YCBD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for YCBD entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where YCBD's RSI Indicator exited the oversold zone, 37 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 68 of 79 cases where YCBD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for YCBD just turned positive on October 21, 2026. Looking at past instances where YCBD's MACD turned positive, the stock continued to rise in 32 of 38 cases over the following month. The odds of a continued upward trend are 84%.
Following a +2.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where YCBD advanced for three days, in 149 of 187 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
YCBD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.517) is normal, around the industry mean (11.138). P/E Ratio (1.647) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. YCBD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YCBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
YCBD | ||
|---|---|---|
OUTLOOK RATING 1..100 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 86 | |
P/E GROWTH RATING 1..100 | 72 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| SHPH | YCBD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| Advances ODDS (%) | 8 days ago 83% | 28 days ago 80% |
| Declines ODDS (%) | 4 days ago 90% | 4 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 73% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
SHPH’s FA Score shows that 0 FA rating(s) are green while YCBD’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
SHPH’s TA Score shows that 5 TA indicator(s) are bullish while YCBD’s TA Score has 5 bullish TA indicator(s).
SHPH (@Pharmaceuticals: Generic) experienced а -7.49% price change this week, while YCBD (@Pharmaceuticals: Generic) price change was +7.34% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
SHPH is expected to report earnings on Nov 12, 2026.
YCBD is expected to report earnings on Dec 18, 2026.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor tells us that SHPH and LFCR have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SHPH and LFCR's prices will move in lockstep.
| Ticker / NAME | Correlation To SHPH | 1D Price Change % | ||
|---|---|---|---|---|
| SHPH | 100% | -1.83% | ||
| LFCR - SHPH | 31% Poorly correlated | N/A | ||
| YCBD - SHPH | 22% Poorly correlated | -2.17% | ||
| LIEN - SHPH | 21% Poorly correlated | N/A | ||
| SXTC - SHPH | 21% Poorly correlated | +11.79% | ||
| RMTI - SHPH | 20% Poorly correlated | -2.07% | ||
More | ||||
A.I.dvisor indicates that over the last year, YCBD has been loosely correlated with TLRY. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if YCBD jumps, then TLRY could also see price increases.
| Ticker / NAME | Correlation To YCBD | 1D Price Change % | ||
|---|---|---|---|---|
| YCBD | 100% | -2.17% | ||
| TLRY - YCBD | 58% Loosely correlated | -3.63% | ||
| TRLV - YCBD | 48% Loosely correlated | +1.95% | ||
| GLAS - YCBD | 43% Loosely correlated | -0.43% | ||
| CRON - YCBD | 40% Loosely correlated | +3.35% | ||
| DERM - YCBD | 24% Poorly correlated | -8.05% | ||
More | ||||